GlassScriptPhysician profile
Denise R Schleeper
NPI 1144642539
$3,247.15
in general payments reported to CMS, 2019-2025
31 companies · $394 in 2025
The $394 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.08 · 2022: $123 · 2023: $1,614 · 2024: $1,078 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,085.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $889.98 | 2022-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $466.01 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $345.88 | 2024-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $307.71 | 2023-2024 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $228.52 | 2021-2024 | Farxiga |
| Medtronic, INC. | $124.76 | 2023-2025 | Minimed 780g, Intellis Adaptivestim |
| Abbvie INC. | $122.68 | 2023-2024 | |
| Insulet Corporation | $90.20 | 2023-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $62.55 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $61.29 | 2023-2024 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $50.97 | 2023 | |
| Intuity Medical INC | $42.50 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Nevro Corp. | $41.96 | 2023 | Senza |
| Amgen INC. | $37.28 | 2023-2025 | Evenity, Prolia |
| Ibsa Pharma INC. | $36.40 | 2023 | Tirosint, Licart |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $31.56 | 2023-2024 | Afrezza |
| Corcept Therapeutics | $27.80 | 2025 | Korlym |
| Glaxosmithkline, LLC. | $26.66 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $26.62 | 2024 | Austedo Xr |
| Tandem Diabetes Care, INC. | $24.97 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Eisai INC. | $23.59 | 2023 | |
| Janssen Pharmaceuticals, INC | $22.37 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.35 | 2025 | |
| Radius Health, INC. | $21.58 | 2025 | |
| Ucb, INC. | $19.68 | 2023 | Briviact |
| Alexion Pharmaceuticals, INC. | $19.42 | 2023 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.43 | 2023 | |
| Redhill Biopharma INC. | $16.24 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.27 | 2023 | Xifaxan |
| Amneal Pharmaceuticals LLC | $13.25 | 2024 | Unithroid |
| Beta Bionics, INC. | $10.67 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Schleeper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.